BET Inhibition Enhances Chemotherapy-Induced Antitumor Immunity by Limiting Macrophage Recruitment in Triple-Negative Breast Cancer

Abstract Background Chemotherapy can promote antitumor immunity in part by inducing immunogenic forms of tumor cell death, providing a rationale for combining cytotoxic agents with immunomodulatory therapies. However, chemotherapy-treated tumors may also develop myeloid-dominated microenvironments that restrict effective T cell responses. Here, we investigated whether bromodomain and extraterminal domain inhibition (BETi) could improve the immune response elicited by liposomal doxorubicin (Doxil) in triple-negative breast cancer (TNBC). Methods We evaluated JQ1 combined with Doxil in orthotopic 4T1 and EMT6 TNBC models, with other BET inhibitors and cisplatin used to examine broader applicability. Transcriptomic profiling, flow cytometry, immunofluorescence, and molecular assays characterized immune responses. T cell depletion, nude mice, and tumor rechallenge assessed immune dependence and memory. Macrophage recruitment was investigated using tumor profiling and in vitro migration assays. Results JQ1 enhanced Doxil-mediated tumor control in both models, prolonged survival in 4T1 mice, and induced complete, recurrence-free regression in EMT6 mice following repeated treatment. Additional BET inhibitors also enhanced chemotherapy efficacy. Antitumor benefit was lost in nude mice and attenuated by CD8 + T cell depletion. Combination treatment increased intratumoral T cell infiltration and activation, effector memory responses, granzyme B expression, and tumor apoptosis, while conferring resistance to rechallenge. JQ1 can reduce chemotherapy-associated macrophage accumulation, decreased CD206 and increased CD86 expression, and inhibited macrophage migration toward CCL2 and chemotherapy-treated tumor cells. Conclusions These findings suggest that BETi can improve chemotherapy-induced antitumor immunity by limiting macrophage recruitment and thereby creating a tumor microenvironment more permissive for CD8 + T cell-mediated tumor control.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11432116/v1
Primary Topic
Protein Degradation and Inhibitors
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

BET Inhibition Enhances Chemotherapy-Induced Antitumor Immunity by Limiting Macrophage Recruitment in Triple-Negative Breast Cancer

Yaofeng Zhou, Songyin Huang, 周火生, Fuxiang Wang et al.
Research Square
Protein Degradation and Inhibitors
preprint

BET Inhibition Enhances Chemotherapy-Induced Antitumor Immunity by Limiting Macrophage Recruitment in Triple-Negative Breast Cancer

Yaofeng Zhou, Songyin Huang, 周火生, Fuxiang Wang, Jiajun Huang, Jueqiong Xu, Tengyao Wang, Qiang Liu, Yan Bao, Yue Chen, Jiawei Wang
preprint en

Abstract

Abstract Background Chemotherapy can promote antitumor immunity in part by inducing immunogenic forms of tumor cell death, providing a rationale for combining cytotoxic agents with immunomodulatory therapies. However, chemotherapy-treated tumors may also develop myeloid-dominated microenvironments that restrict effective T cell responses. Here, we investigated whether bromodomain and extraterminal domain inhibition (BETi) could improve the immune response elicited by liposomal doxorubicin (Doxil) in triple-negative breast cancer (TNBC). Methods We evaluated JQ1 combined with Doxil in orthotopic 4T1 and EMT6 TNBC models, with other BET inhibitors and cisplatin used to examine broader applicability. Transcriptomic profiling, flow cytometry, immunofluorescence, and molecular assays characterized immune responses. T cell depletion, nude mice, and tumor rechallenge assessed immune dependence and memory. Macrophage recruitment was investigated using tumor profiling and in vitro migration assays. Results JQ1 enhanced Doxil-mediated tumor control in both models, prolonged survival in 4T1 mice, and induced complete, recurrence-free regression in EMT6 mice following repeated treatment. Additional BET inhibitors also enhanced chemotherapy efficacy. Antitumor benefit was lost in nude mice and attenuated by CD8 + T cell depletion. Combination treatment increased intratumoral T cell infiltration and activation, effector memory responses, granzyme B expression, and tumor apoptosis, while conferring resistance to rechallenge. JQ1 can reduce chemotherapy-associated macrophage accumulation, decreased CD206 and increased CD86 expression, and inhibited macrophage migration toward CCL2 and chemotherapy-treated tumor cells. Conclusions These findings suggest that BETi can improve chemotherapy-induced antitumor immunity by limiting macrophage recruitment and thereby creating a tumor microenvironment more permissive for CD8 + T cell-mediated tumor control.

Research Square
Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN)
National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province
Good health and well-being
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon